The Onco'Zine Brief @oncozine - Tumblr Blog

Posts

In this episode of The Onco'Zine Brief, Peter Hofland talks with David M. Cognetti, MD, a Professor and Chair in the Department Head and Neck Surgery at Thomas Jefferson University Hospital in Philadelphia. Hofland and Cognetti talk about head and neck cancer and a novel treatment approach called Photoimmunotherapy. According to the American Cancer Society, Head and neck cancer accounts for about 4% of all cancers in the United States. In the United States in 2023, an estimated 67,000 people will be diagnosed with head and neck cancer and about 15,000 patients are expected to die of the disease. Today, many cancers of the head and neck can be cured, especially if they are found early. And while eliminating the cancer is the primary goal of treatment, preserving the function of the nearby nerves, organs, and tissues is also very important. Photoimmunotherapy is a recently developed hybrid cancer therapy to treat diseases by linking specific antibodies with photosensitizers to form photoimmunoconjugates. About The Onco'Zine Brief The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio. For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit to download our Media Kit, visit Patreon at or contact the sales team. For more information about cancer and cancer treatments, visit our online journal Onco'Zine. To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866. The Onco’Zine Brief is made possible, in part, by Java Original Coffee – the home of artisan roasted coffee and Roastmasterz.

#alluminox™#cancer #photoimmunotherapy

In this episode of The Onco'Zine Brief, Peter Hofland talks with two experts about their research and the impact the outcomes from these studies may have on the treatment of patients diagnosed with cancer. First, Hofland talks with Christopher Heery, MD. Dr Heery is a board-certified medical oncologist with primary expertise in the translational and clinical development of immunotherapies, including, but not limited to PD-L1 inhibitors, therapeutic cancer vaccines, immune suppressor modulator, adoptive NK cells, and other therapeutics. As the chief medical officer at Arcellx, he is responsible for medical oversight, clinical strategy, medical affairs, and regulatory strategy for the company’s pipeline of novel – investigational drug. In the second half of the program, Hofland talks with Srdan Verstovsek, Dr Srdan Verstovsek, MD, PhD., a Medical Oncologist and Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, about some of the developments in the treatment of myeloproliferative neoplasm, which are types of blood cancer that begin with an abnormal mutation or change, in a stem cell in the bone marrow. These change leads to an overproduction of any combination of white cells, red blood cells and platelets – and results in a number of diseases, including:

Essential Thrombocythemia (ET) Is a rare blood disease in which the bone marrow produces too many platelets;

Myelofibrosis, a rare disorder in which abnormal blood cells and fibers build up in the bone marrow;

Polycythemia Vera (PV) – a disease in which too many red blood cells are made in the bone marrow and, in many cases, the numbers of white blood cells and platelets are also elevated.

About The Onco'Zine Brief The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio. For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit to download our Media Kit, visit Patreon at or contact the sales team. For more information about cancer and cancer treatments, visit our online journal Onco'Zine. To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866. The Onco’Zine Brief is made possible, in part, by Java Original Coffee – the home of artisan roasted coffee.

#cancer #essential-thrombocythemia #hematology #myelofibrosis #nk-cells #oncology #oncozine #pd-l1 #polycythemia-vera

In December 2022 the annual meeting of the American Society of Hematology took place in the vibrant city of New Orleans and brought together tens of thousands of participants from across the world to present and discuss the results of studies that ranged from initial hypothesis to practice-changing results. In this episode of The Onco’Zine Brief Peter Hofland talks to two people about their research and the impact the outcomes from these studies may have. First, Hofland talks with Thomas G. Martin, MD. Martin is the Associate Director of the University of California San Francisco Myeloma Program and Director of the Unrelated Donor Transplantation program for adults at UCSF Medical Center. Martin's research interests include developing treatments for myeloma and leukemia as well as expanding the use of bone marrow transplants. He has a special interest in umbilical cord blood transplants, and he is involved in efforts to improve outcomes for patients who have transplants from unrelated donors. In this episode Hofland and Martin talk about updated results from a Phase 1b expansion study evaluating subcutaneous administration of Isatuximab-irfc (Sarclisa®; Sanofi) by an on-body delivery system in combination with pomalidomide (Pomalyst®; Bristol-Myers Squibb Company) and dexamethasone in patients with relapsed/refractory multiple myeloma. How does subcutaneous delivery vs. intravenous administration of Isatuximab benefits patients? Hofland and Martin also talk about the results of a Subgroup Analysis of the IKEMA trial. Then, With Monica Soni, MD, Director of Specialty Care for the Los Angeles County Department of Health Services, the second-largest municipal health system in the United States. She is also an assistant clinical professor within the UCLA Department of Medicine. Soni is commitment to improving quality, equity and affordability in health care. In this episode Hofland and Soni talks about the results of a study in which the investigators looked at the utilization of bone-modifying agents (BMA) in the treatment of multiple myeloma, particularly among Medicaid patients. What invesrigatriors found was shocking! About The Onco'Zine Brief The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio. For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit to download our Media Kit, visit Patreon at or contact the sales team. For more information about cancer and cancer treatments, visit our online journal Onco'Zine. To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866. The Onco’Zine Brief is made possible, in part, by Java Original Coffee – the home of artisan roasted coffee. Clinical trial Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients (IKEMA) -NCT03275285

#affordability #ash #cancer #equity #hematology #isatuximab-#quality #ucla #ucsf #value-based

In this –this episode of the Onco’Zine Brief, Peter Hofland is talking with Dr. Matthias Bucerius. Dr. Bucerius is Vice President and General Manager at MilliporeSigma. He is responsible for Contract Development and Manufacturing Organsation (CDMO) business of the company, leading a fully integrated global team with Manufacturing Operations, Commercial, Marketing & Strategy, Technology & Innovation organizations. The company is helping its clients in developing and manufacturing a variety of products, including antibody-drug conjugates. Antibody-drug conjugates or ADCs are targeted therapies that have opened new ways in targeting diseases like cancer and hematological malignancies. What is unique about ADCs is that they leverage the specific targetability benefits offered by antibodies and combine that with the high potency of small-molecule drugs. This combination makes these agents uniquely targetable therapies. And unlike traditional chemotherapy, these ADCs target tumors by delivering the attached payload to destroy cancer cells while sparing the healthy or normal cells, thereby potentially reducing negative side effects for patients.